This HTML5 document contains 156 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n10http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34150300
rdf:type
wikibase:Item
schema:description
vetenskaplig artikel 2002年论文 ২০০২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scientific article 2002年論文 artikulong pang-agham vědecký článek artículo científico publicado en 2002 บทความทางวิทยาศาสตร์ teaduslik artikkel vitskapeleg artikkel article scientifique (publié 2002) wissenschaftlicher Artikel مقالة علمية naučni članak мақолаи илмӣ 2002年论文 2002년 논문 article scientific ശാസ്ത്രപ്രബന്ധം​ 2002年論文 wetenschappelijk artikel articol științific 2002年论文 article científic 2002年論文 artikull shkencor מאמר מדעי artigo científico (publicado na 2002) bài báo khoa học artykuł naukowy videnskabelig artikel (udgivet 2002) scienca artikolo სამეცნიერო სტატია επιστημονικό άρθρο научная статья artigo científico سائنسی مضمون 2002年论文 мақолаи илмӣ مقالهٔ علمی 2002年论文 научни чланак bilimsel makale artigo científico (publicado na 2002) 2002年論文 2002年论文 artículu científicu espublizáu en 2002 mokslinis straipsnis 2002年の論文 2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված 2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած tieteellinen artikkeli научни чланак articolo scientifico vitenskapelig artikkel tudományos cikk научна статия 2002 nî lūn-bûn vedecký článok 2002年論文 наукова стаття, опублікована у вересні 2002
p:P577
wds:Q34150300-EBC0F01E-0C3F-46F4-ADE4-9C6BA22466F7
wdt:P577
2002-09-01T00:00:00Z
p:P407
wds:Q34150300-4AE4703E-797C-46BE-9458-1BDFAC6AB00C
wdt:P407
wd:Q1860
p:P2860
wds:Q34150300-00568608-55C8-4F60-AF0C-C5690C6BCF72 wds:Q34150300-066D10CA-DE53-4711-AB1B-36218C46DB29 wds:Q34150300-08854B21-9DD8-4BC9-8A60-CB3114A90A13 wds:Q34150300-3A35C383-BEF8-4313-80C4-58B63863C045 wds:Q34150300-3B3A4CF8-AA16-4FDD-B018-8FDF11ED34DA wds:Q34150300-3D8DE614-7CE5-4EDB-922D-144FB4CC8116 wds:Q34150300-4DD8B4C8-4DEF-41C4-BF25-18060BAE218A wds:Q34150300-52D665BB-541B-41D6-97CC-E490A5B6D10A wds:Q34150300-6B17C972-4039-4577-9663-84ED51F55D1C wds:Q34150300-746B782B-9BA5-4FAA-BE84-6E0D9468DCF4 wds:Q34150300-79031464-D405-4AC5-BC2C-B31A5173AE3D wds:Q34150300-7A472482-010E-4CEB-8035-91592CF6CD68 wds:Q34150300-7D852AAE-2AF6-4305-A531-1A7910E57308 wds:Q34150300-8EF0360F-059E-44FA-9F90-18BDE3118E20 wds:Q34150300-8FE2F779-66FD-4A72-9241-D2AA195D5A12 wds:Q34150300-994FC54D-9129-4941-B955-CBE40557644C wds:Q34150300-A1470EF5-0822-4CCE-80B2-DDC0625BD57B wds:Q34150300-C9B276E0-C854-4F12-8829-F8926AD3D883 wds:Q34150300-D36C16E2-5702-462B-999D-887477DA7180 wds:Q34150300-DF64C6E5-02AF-41FF-819D-F39EDEBE0E4C wds:Q34150300-E8ACBBA4-0CBA-4EA9-867E-50F1B5A9DDD7 wds:Q34150300-ED266395-6F60-48F1-85C8-1DC65AAB611A wds:Q34150300-F6665DC5-7532-4461-8B7C-2138D21EEDA1 wds:Q34150300-F6D88CA0-5C71-48D6-8191-16EA748CE71B
wdt:P2860
wd:Q74666357 wd:Q34522261 wd:Q34718800 wd:Q43832647 wd:Q31383623 wd:Q74598270 wd:Q47842750 wd:Q30638921 wd:Q40541721 wd:Q78195753 wd:Q44372640 wd:Q54180877 wd:Q60164685 wd:Q68005730 wd:Q34539986 wd:Q71870087 wd:Q41703415 wd:Q73023637 wd:Q74062350 wd:Q42278661 wd:Q42289123 wd:Q73164612 wd:Q29615215 wd:Q73301653
p:P2093
wds:Q34150300-84148D27-FB60-4961-8C04-585882B0F8E6
wdt:P2093
OPTIMAAL Steering Committee of the OPTIMAAL Study Group
rdfs:label
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
skos:prefLabel
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
schema:name
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
p:P50
wds:Q34150300-FF485A2D-21F8-48BE-82C5-71DF78964140 wds:Q34150300-8D26AE71-01AA-4FDF-B0F4-4A8949DD97C9
wdt:P50
wd:Q43248428 wd:Q6243255
p:P1476
wds:Q34150300-7EECADE5-1BED-4612-90DE-4D9F66EB6EAE
wdt:P1476
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan
p:P304
wds:Q34150300-D2E12EA7-A60A-4CAB-9727-717BEEFA4F49
wdt:P304
752-760
p:P31
wds:Q34150300-DA0A9349-C7C5-4F13-B9BF-912355D92703
wdt:P31
wd:Q13442814
p:P921
wds:Q34150300-7993A874-CCFD-4EA8-B1D6-32F97C22DD7D wds:Q34150300-3B6F0999-EA89-4528-AE9A-254D314AE488 wds:Q34150300-35B1AD84-9216-4229-974A-816087319659 wds:Q34150300-C9B02992-DB4B-4DCF-BEF3-2913D22CDD68
wdt:P921
wd:Q18558122 wd:Q12152 wd:Q410074 wd:Q181600
p:P698
wds:Q34150300-F9AFA962-1C42-45A4-9A9E-1B8208B4B070
wdtn:P698
n11:12241832
wdt:P698
12241832
p:P1433
wds:Q34150300-57365C7F-8AE3-4F80-8172-94A5D8CEC443
wdt:P1433
wd:Q939416
p:P433
wds:Q34150300-1D5184C0-0139-4E38-9897-76BA7FC2943B
p:P478
wds:Q34150300-95E51B20-5E1D-4F32-B1F1-9240C7814DA9
wdt:P433
9335
wdt:P478
360
p:P356
wds:Q34150300-09FB3CE0-46A7-41C8-8170-42251BC1769E
wdtn:P356
n10:S0140-6736(02)09895-1
wdt:P356
10.1016/S0140-6736(02)09895-1